Smooth Muscle Enriched Long Noncoding RNA (SMILR) Regulates Cell Proliferation

MD Ballantyne, K Pinel, R Dakin, AT Vesey, L Diver… - Circulation, 2016 - Am Heart Assoc
MD Ballantyne, K Pinel, R Dakin, AT Vesey, L Diver, R Mackenzie, R Garcia, P Welsh
Circulation, 2016Am Heart Assoc
Background—Phenotypic switching of vascular smooth muscle cells from a contractile to a
synthetic state is implicated in diverse vascular pathologies, including atherogenesis,
plaque stabilization, and neointimal hyperplasia. However, very little is known about the role
of long noncoding RNA (lncRNA) during this process. Here, we investigated a role for
lncRNAs in vascular smooth muscle cell biology and pathology. Methods and Results—
Using RNA sequencing, we identified> 300 lncRNAs whose expression was altered in …
Background
Phenotypic switching of vascular smooth muscle cells from a contractile to a synthetic state is implicated in diverse vascular pathologies, including atherogenesis, plaque stabilization, and neointimal hyperplasia. However, very little is known about the role of long noncoding RNA (lncRNA) during this process. Here, we investigated a role for lncRNAs in vascular smooth muscle cell biology and pathology.
Methods and Results
Using RNA sequencing, we identified >300 lncRNAs whose expression was altered in human saphenous vein vascular smooth muscle cells following stimulation with interleukin-1α and platelet-derived growth factor. We focused on a novel lncRNA (Ensembl: RP11-94A24.1), which we termed smooth muscle–induced lncRNA enhances replication (SMILR). Following stimulation, SMILR expression was increased in both the nucleus and cytoplasm, and was detected in conditioned media. Furthermore, knockdown of SMILR markedly reduced cell proliferation. Mechanistically, we noted that expression of genes proximal to SMILR was also altered by interleukin-1α/platelet-derived growth factor treatment, and HAS2 expression was reduced by SMILR knockdown. In human samples, we observed increased expression of SMILR in unstable atherosclerotic plaques and detected increased levels in plasma from patients with high plasma C-reactive protein.
Conclusions
These results identify SMILR as a driver of vascular smooth muscle cell proliferation and suggest that modulation of SMILR may be a novel therapeutic strategy to reduce vascular pathologies.
Am Heart Assoc